Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 04/29/2012 - 04/29/2015

This course is closed. Please look for other available products in CPNP University.

Session Summary

Schizophrenia is a devastating, lifelong disease. There is accumulating evidence suggesting the involvement of the nicotinic system in the pathophysiology of schizophrenia. This, in conjunction with a high rate of cigarette smoking among people with schizophrenia, introduces an interesting convergence of research and clinical treatment dilemmas around nicotine and schizophrenia.  Despite the evidence implicating the nicotinic system with symptoms of schizophrenia, no current treatment strategies focus on this system.  Additionally, smoking cessation programs in people with schizophrenia remain less than ideal.  During this session, Deanna Kelly, PharmD, BCPP will address the role of nicotine in cognitive function, and present emerging data on the effects of nicotinic agents on both cognition and smoking cessation.

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • Receive a passing grade (60%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

This session was presented live at the 2012 CPNP Annual Meeting. A PDF file of the slides and audio of the speaker's presentation is provided. ACPE transcripts can be retrieved by participants online at cpnp.org and the credit will be automatically submitted to your account at CPE Monitor shortly after the evaluation is completed.

Faculty Information and Disclosures

Learning Objectives

  1. Explain the normal function of nicotine related to thought processes.
  2. Characterize the pathophysiological changes in the nicotine system responsible for manifestations of schizophrenia.
  3. Explain the effects of smoking cessation on symptoms of schizophrenia.
  4. Recommend a plan of action for a patient with schizophrenia who smokes tobacco.

Continuing Education Credit and Disclosures

Activity Dates: 04/29/2012 - 04/29/2015
ACPE Contact Hours: 1.0
ACPE Number: 0284-9999-12-004-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPE Credit

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


CME Credit

Sponsored by the University of Arizona College of Medicine at the Arizona Health Sciences Center.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the Joint sponsorship of The University of Arizona College of Medicine at the Arizona Health Sciences Center and the College of Psychiatric and Neurologic Pharmacists. ACCME credit is no longer available for this course.

Nursing Credit

ACPE and ACCME approved contact hours are accepted for ANCC Certification Renewal (as quoted on the ANCC website):  “Other health disciplines' continuing education hours may be used if the content is applicable to your area of certification. ACPE and ACCME are specifically listed as approved credit types.

Grant Support

Annual Meeting Grant Supporter

BCPP Recertification Grant Supporter